Medical

Amgen

$251.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$7.54 (-2.92%) Today
-$0.06 (-0.02%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Amgen and other stocks, options, and ETFs commission-free!

About AMGN

Amgen Inc. Common Stock, also called Amgen, is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA. The listed name for AMGN is Amgen Inc. Common Stock.

CEO
Robert A. Bradway
Employees
23,400
Headquarters
Thousand Oaks, California
Founded
1980
Market Cap
143.28B
Price-Earnings Ratio
20.74
Dividend Yield
2.49
Average Volume
2.41M
High Today
$259.44
Low Today
$250.32
Open Price
$255.31
Volume
3.24M
52 Week High
$264.97
52 Week Low
$177.05

Collections

AMGN News

MarketWatchJan 21

BioNTech SE ADR rises Thursday, outperforms market

The BioNTech SE ADR BNTX, +2.13% rallied 2.13% to $105.43 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P

AMGN Earnings

$0.00
$1.46
$2.91
$4.37
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Feb 2, After Hours

You May Also Like

DHX
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure